{"id":"isatuximab-carfilzomib-lenalidomide-dexamethasone","safety":{"commonSideEffects":[{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Cardiac toxicity"}]},"_chembl":{"chemblId":"CHEMBL3545131","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Isatuximab is a monoclonal antibody against CD38 that promotes myeloma cell death through antibody-dependent cellular cytotoxicity and direct apoptosis. Carfilzomib is a proteasome inhibitor that causes accumulation of toxic proteins in myeloma cells. Lenalidomide enhances immune responses against myeloma and has direct anti-proliferative effects. Dexamethasone provides additional anti-myeloma activity and reduces inflammation.","oneSentence":"This is a four-drug combination regimen that targets multiple pathways in multiple myeloma: isatuximab blocks CD38 on myeloma cells, carfilzomib inhibits the proteasome, lenalidomide is an immunomodulatory agent, and dexamethasone is a corticosteroid.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:15.929Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (relapsed/refractory or newly diagnosed)"}]},"trialDetails":[{"nctId":"NCT04430894","phase":"PHASE2","title":"KRDI in Transplant-Eligible MM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-07-10","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT05675319","phase":"PHASE3","title":"Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy","status":"TERMINATED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2023-03-03","conditions":"Multiple Myeloma","enrollment":28},{"nctId":"NCT04483739","phase":"PHASE3","title":"Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Myeloma Network B.V.","startDate":"2020-09-25","conditions":"Multiple Myeloma","enrollment":302},{"nctId":"NCT05669989","phase":"PHASE2","title":"International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-04-05","conditions":"Plasma Cell Myeloma","enrollment":70},{"nctId":"NCT04934475","phase":"PHASE3","title":"MInimal Residual Disease Adapted Strategy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Intergroupe Francophone du Myelome","startDate":"2021-12-08","conditions":"Multiple Myeloma","enrollment":791},{"nctId":"NCT03104842","phase":"PHASE2","title":"Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2017-08-15","conditions":"Multiple Myeloma","enrollment":246}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Isa-KRD"],"phase":"phase_3","status":"active","brandName":"Isatuximab Carfilzomib Lenalidomide Dexamethasone","genericName":"Isatuximab Carfilzomib Lenalidomide Dexamethasone","companyName":"European Myeloma Network B.V.","companyId":"european-myeloma-network-b-v","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a four-drug combination regimen that targets multiple pathways in multiple myeloma: isatuximab blocks CD38 on myeloma cells, carfilzomib inhibits the proteasome, lenalidomide is an immunomodulatory agent, and dexamethasone is a corticosteroid. Used for Multiple myeloma (relapsed/refractory or newly diagnosed).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}